Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep:7:e2300016.
doi: 10.1200/CCI.23.00016.

Data-Driven Personalized Care in Lung Cancer: Scoping Review and Clinical Recommendations on Performance Status and Activity Level of Patients With Lung Cancer Using Wearable Devices

Santiago Ponce Aix  1 , Francisco J Núñez-Benjumea  2   3 , Sergio Cervera-Torres  2 , Andrés Flores  4 , Pablo Arnáiz  4 , Luis Fernández-Luque  2
Affiliations

Data-Driven Personalized Care in Lung Cancer: Scoping Review and Clinical Recommendations on Performance Status and Activity Level of Patients With Lung Cancer Using Wearable Devices

Santiago Ponce Aix et al. JCO Clin Cancer Inform. 2023 Sep.

Abstract

Purpose: Performance status (PS) is a crucial assessment for research and clinical practice in lung cancer (LC), including its usage for the assessment of the suitability and toxicity of treatment or eligibility for clinical trials of patients with LC. These PS assessments are subjective and lead to substantial discrepancies between observers. To improve the objectivity of PS assessments, Electronic Activity Monitoring devices (EAMs) are increasingly used in oncology, but how these devices are used for PS assessments in LC is an issue that remains unclear. The goal of this study is to address the challenges and opportunities of the use of digital tools to support PS assessments in patients with LC.

Methods: The literature review followed PRISMA-ScR methodology. Searches were performed in the ScienceDirect, PsycInfo, ACM, IEEE Xplore, and PubMed databases. Furthermore, a panel discussion was performed to address the clinical use cases.

Results: Thirty-two publications were found. Most of the studies used wrist accelerometry-based wearables (59%) and monitored sleep activity (SA; 28%) or physical activity (PA; 72%). Critical findings include positive usefulness of the use of wearables to categorize moderate-to-vigorous/light PA, which was associated with better sleep and health. In addition, steps and time awake immobile were found to be associated with risk of hospitalization and survival. Use cases identified included the health assessment of patients and clinical research.

Conclusion: There are positive experiences in the use of EAM to complement PS assessment in LC. However, there is a need for adapting thresholds to the particularities of patients with LC, for example, differentiating moderate-to-vigorous and light. Moreover, developing methodologies combining PS assessments and the use of EAM adapted to clinical and research practice is needed.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Santiago Ponce Aix

Consulting or Advisory Role: Roche, Bristol Myers Squibb

Speakers' Bureau: Bristol Myers Squibb, Roche, AstraZeneca

Travel, Accommodations, Expenses: AstraZeneca, Roche

Francisco J. Núñez-Benjumea

Research Funding: Vifor Pharma (Inst), GlaxoSmithKline (Inst), Astellas Pharma (Inst), Janssen (Inst)

Pablo Arnáiz

Employment: Roche

Stock and Other Ownership Interests: Roche

Luis Fernández-Luque

Employment: Adhera Health

Stock and Other Ownership Interests: Adhera Health

Patents, Royalties, Other Intellectual Property: Two patents pending

Uncompensated Relationships: Adhera Health (Inst)

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Mobile Solution (Adhera Health Inc) that can be used to capture ePROs in combination with wearable devices. ePROS, electronic patient-related outcomes.
FIG 2.
FIG 2.
CONSORT diagram. LC, lung cancer.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018 - PubMed
    1. Friedlaender A, Liu SV, Passaro A, et al. : The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors. Clin Lung Cancer 21:e539-e543, 2020 - PubMed
    1. Molina JR, Yang P, Cassivi SD, et al. : Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc 83:584-594, 2008 - PMC - PubMed
    1. Travis WD, Brambilla E, Nicholson AG, et al. : The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243-1260, 2015 - PubMed
    1. Cetin K, Ettinger DS, Hei YJ, et al. : Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol 3:139-148, 2011 - PMC - PubMed

Publication types